Search Results - chi-ping+day

5 Results

Sort By:

Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters

Abstract: The National Cancer Institute’s Protein Expression Laboratory seeks parties to co-develop dual luminescent/fluorescent cancer biomarkers. In research settings, visualization of tumors or tumor cells is often done using either bioluminescence or fluorescence. However, both of these methods have shortcomings: bioluminescence is not sensitive...

Published: 5/22/2024 | Inventor(s): Dominic Esposito, Chi-Ping Day, Glenn Merlino

Keywords(s): Bioluminescence, Fluorescence, tumor visualization, vectors

Category(s): TherapeuticArea > Oncology, Application > Research Materials, Collaboration Sought > Licensing

Mouse Model for the Preclinical Study of Metastatic Disease

Abstract: The successful development of new cancer therapeutics requires reliable preclinical data that are obtained from mouse models for cancer. Human tumor xenografts, which require transplantation of human tumor cells into an immune compromised mouse, represent the current standard mouse model for cancer. Since the immune system plays an important...

Published: 5/23/2024 | Inventor(s): Chi-Ping Day, Glenn Merlino, Terry Van Dyke, Zoe Ohler

Keywords(s): Carcinoma, neoplasm, non small cell lung, treatment outcome, xenograft mouse

Category(s): Application > Research Materials, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma

Abstract: The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Before testing drugs in humans, drug developers are required...

Published: 5/23/2024 | Inventor(s): Chi-Ping Day, Glenn Merlino, Zoe Ohler, Rajaa El Meskini, Terry Van Dyke, Thomas Tuting

Keywords(s): Allograft, GDA, Genetically Engineered Mouse-Derived Allograft, MELANOMA, Metastasis, mouse model, Preclinical, therapeutics

Category(s): Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors

Abstract: Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape. PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1...

Published: 4/8/2024 | Inventor(s): Mitchell Ho, Glenn Merlino, Dan Li, Hejiao English, Chi-Ping Day

Keywords(s): adoptive cell therapy, Chimeric Antigen Receptor T Cells, HO, ICI, Immune Checkpoint Inhibitor, Immunotherapy, NANOBODY, PD-L1, phage display, Programed Death-Ligand, Single Domain Antibody

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Immunocompetent Mouse Model for Tracking Cancer Progression

Abstract: The National Cancer Institute seeks interested parties to co-develop transgenic mice having immunocompetent rat growth hormone-firefly Luciferase-enhanced green fluorescent protein. The technology is a transgenic mouse model tolerized to firefly Luciferase (ffLuc)- and enhanced green fluorescent protein (eGFP)-labeled tissue whilst maintaining...

Published: 5/23/2024 | Inventor(s): Glenn Merlino, Chi-Ping Day, Lalage Wakefield

Keywords(s): Achondroplasia, Bioimaging, Immunocompetent, Rat growth hormone

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Research Materials